Frankfurt - Delayed Quote ? EUR Intellia Therapeutics, Inc. (38I.F) Follow Compare 19.32 +0.12 (+0.65%) At close: October 21 at 10:04 AM GMT+2 All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Intellia Therapeutics (NTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Zacks ? 4 days ago NTLA This Beaten-Down Growth Stock Could Skyrocket 234%, According to Wall Street Intellia Therapeutics' innovative gene editing technology could revolutionize medicine, but investors need a strong stomach for volatility. Motley Fool ? 4 days ago NTLA Is Intellia Therapeutics, Inc. (NTLA) the Most Promising Biotech Stock According to Hedge Funds? We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds. In this article, we are going to take a look at where Intellia Therapeutics, Inc. (NASDAQ:NTLA) stands against the other promising biotech stocks. Biotechnology stocks are known for their high risk, making them some of the most volatile in the […] Insider Monkey ? 5 days ago NTLA Intellia Therapeutics Announces New Date for Upcoming Investor Webcast - Investor webcast to review the NTLA-2002 Phase 2 data is now planned for Thursday, October 24 at 8:30 a.m. ET CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced a new date for its upcoming investor webcast to review the data from the Phase 2 study of NTLA-2002. The webcast will now be held on Thursday, October 24 at 8:30 a.m. GlobeNewswire ? 11 days ago NTLA Intellia Therapeutics Inc (NTLA) Q2 2024 Earnings Call Highlights: Strategic Advances and ... Intellia Therapeutics Inc (NTLA) showcases promising clinical progress and financial resilience amidst evolving market dynamics. GuruFocus.com ? 12 days ago NTLA 2 Cathie Wood Stocks That Could Soar 32% and 282%, According to Wall Street These stocks haven't performed well this year. Motley Fool ? 12 days ago NTLA NTLA Begins Phase III Study on Hereditary Angioedema Candidate Intellia starts the pivotal phase III HAELO study on NTLA-2002 for the treatment of hereditary angioedema (HAE). Zacks ? 13 days ago NTLA Intellia Therapeutics begins Phase III trial of hereditary angioedema gene therapy Variation in the frequency of hereditary angioedema attacks between weeks five and 28 will be the trial's primary endpoint. Clinical Trials Arena ? 13 days ago NTLA Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of?NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE) NTLA-2002 is a single-dose treatment designed to prevent potentially life-threatening swelling attacks in people with hereditary angioedema (HAE)NTLA-2002 is Intellia’s second in vivo candidate to enter late-stage clinical development from its modular gene editing platform CAMBRIDGE, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the GlobeNewswire ? 14 days ago NTLA Intellia starts late-stage test of CRISPR therapy for rare swelling disease The study, of Intellia’s treatment for hereditary angioedema, is the second Phase 3 trial the biotech has begun testing its “in vivo” gene editing medicines. BioPharma Dive ? 14 days ago NTLA Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on October 1, 2024 it awarded inducement grants to nine new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment. The inducement grants consisted of time-based restricted stock units (“RSUs”) for 54,944 shares of Intellia’s common stock, w GlobeNewswire ? 18 days ago NTLA Intellia Therapeutics (NASDAQ:NTLA shareholders incur further losses as stock declines 10% this week, taking three-year losses to 86% It's not possible to invest over long periods without making some bad investments. But really big losses can really... Simply Wall St. ? 18 days ago NTLA Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions New data to be presented will include biomarkers of disease progression and functional capacity from the ongoing Phase 1 study of nex-z, an investigational in vivo CRISPR gene editing therapy for ATTR amyloidosis CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that interim data from the ongoing Phase 1 study of nexiguran zic GlobeNewswire ? 20 days ago NTLA 2 Innovative Cathie Wood Stocks to Buy If You Can Stomach the Risk The Ark Invest portfolio is known for taking aggressive bets. Motley Fool ? 22 days ago NTLA RXRX The Brawl Taking Shape Over Pfizer’s Multibillion-Dollar Heart Monopoly The drugmaker’s fastest-growing blockbuster could soon face competition from two biotech firms in the treatment of a little-known heart condition. The Wall Street Journal ? last month NTLA PFE ALNY Intellia Therapeutics to Present Data from the Phase 2 Study of?NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)?at the 2024 ACAAI Annual Scientific Meeting First presentation of detailed Phase 2 results following previous positive topline announcement that study of NTLA-2002 met primary and all secondary endpoints Intellia to host investor webcast on Monday, October 28, at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that data from the Phase 2 study of NTLA-200 GlobeNewswire ? last month NTLA Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) latest 6.7% decline adds to one-year losses, institutional investors may consider drastic measures Key Insights Significantly high institutional ownership implies Intellia Therapeutics' stock price is sensitive to... Simply Wall St. ? last month NTLA Intellia Therapeutics, Inc. (NTLA): Pioneering Gene Editing Solutions for Health Advancements We recently compiled a list of 10 Stocks That Will Change the World. In this article, we are going to take a look at where Intellia Therapeutics, Inc. (NASDAQ:NTLA) stands against the other stocks. If we were to try and summarize one of the biggest ways how to make money on the stock market, it’d […] Insider Monkey ? 2 months ago NTLA Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report As you might know, Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) last week released its latest second-quarter, and things... Simply Wall St. ? 2 months ago NTLA Intellia's (NTLA) Q2 Earnings & Revenues Fall Shy of Estimates Intellia's (NTLA) second-quarter 2024 earnings and revenues lag estimates. The company provides developmental and regulatory updates on its pipeline candidates. Zacks ? 2 months ago NTLA Performance Overview Trailing total returns as of 10/21/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return 38I.F S&P 500 YTD -33.24% +22.73% 1-Year -23.32% +38.58% 3-Year -82.83% +29.05%
